# A Phase I Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetic Characteristics, and Preliminary Efficacy of HLX35 in Combination With HLX10 in Patients With Advanced or Metastatic Solid Tumors

> **NCT05442996** · PHASE1 · UNKNOWN · sponsor: **Shanghai Henlius Biotech** · enrollment: 30 (estimated)

## Conditions studied

- Solid Tumor, Adult

## Interventions

- **DRUG:** HLX35
- **DRUG:** HLX10

## Key facts

- **NCT ID:** NCT05442996
- **Lead sponsor:** Shanghai Henlius Biotech
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2023-01-06
- **Primary completion:** 2024-04-22
- **Final completion:** 2025-04-22
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2022-07-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05442996

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05442996, "A Phase I Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetic Characteristics, and Preliminary Efficacy of HLX35 in Combination With HLX10 in Patients With Advanced or Metastatic Solid Tumors". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT05442996. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*